P059: Comprehensive somatic mutational profiling of triple-negative breast cancer reveals clinically actionable genetic alterations*

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, limiting the availability of standard targeted therapies. TNBC demonstrates marked clinical heterogeneity and a high frequency of alterations in DNA damage repair pathways, making genomic characterization essential for diagnosis, therapeutic stratification, and identification of hereditary cancer susceptibility. Comprehensive mutational profiling using exome sequencing (ES) can reveal actionable somatic and potentially germline-associated variants that inform clinical genetic testing and precision oncology.